Archive — US — techcrunch
AI isn’t close to curing cancer. This startup says it knows what it will take.
Vivodyne, a biotech startup, claims that AI in drug discovery faces a data deficit. Its HIVE robotic labs can cultivate human tissue and generate critical biological data absent in current AI models, addressing limitations that lead to high rates of failure in drug testing. By developing accurate simulations of human responses, Vivodyne aims to improve drug development and bring new therapies to clinical trials more reliably.
Key points
- Vivodyne identifies a data problem in AI drug discovery which relies too much on animal testing rather than human tissue samples.
- CEO Andrei Georgescu criticizes AI claims of curing cancer without adequate human-based evidence, emphasizing a disconnect between AI predictions and real-world biology.
- Vivodyne's HIVE labs can autonomously create and study human tissue, achieving high predictive accuracy in simulating human organ responses.
- The pharmaceutical industry faces a 90% failure rate for drugs passing animal trials, highlighting the need for more accurate predictive models.
- Vivodyne has partnered with major pharmaceutical firms to improve confidence in drug trial outcomes prior to clinical testing.
Why it matters
- Current trends in biotechnology emphasize the integration of AI and human-specific data for drug discovery.
- Historical attempts at using AI for disease treatment have met skepticism due to results not translating well from models to human trials.
- 2025 is projected to show significant advancements in AI applications, including how they interact with complex human biology and disease modeling.
Vivodyne’s innovative approach using HIVE labs aims to bridge the gap between AI predictions and human biology, potentially revolutionizing drug discovery and improving the success rate of clinical trials.